In contrast, use of SGLT2 inhibitors in the same population did not modify risk of the studied hematologic malignancies but did increase the risk of death in patients with both type 2 diabetes mellitus and either acute myeloid leukemia or multiple myeloma, independently of heart failure. This evidence concerns the gene SLC5A2 and hematologic disorder.